False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part I: Focus on epilepsy

Journal of Clinical Psychopharmacology

Volumn 34, Issue 2, 2014, Pages 177-183

  De Leon, Jose ^a,b  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ANTICONVULSANT THERAPY; BIPOLAR DISORDER; CLINICAL RESEARCH; DRUG INDUSTRY; DRUG METABOLISM; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW;

ANTICONVULSANTS; DRUG INTERACTIONS; ENZYME INDUCTION; EPILEPSY; FALSE NEGATIVE REACTIONS; HUMANS;

EID: 84896398660     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000093     Document Type: Review

References (50)

1. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2: e124.
2. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling (editorial). Clin Pharmacol Ther. 2007;81: 298-304.
3. de Leon J. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011;31: 263-265.
4. Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin Pharmacother. 2006;7: 1977-1987.
5. Fulton JA, Hoffman RS, Nelson LS. Tiagabine overdose: a case of status epilepticus in a non-epileptic patient. Clin Toxicol (Phila). 2005;43: 869-871.
6. Flowers CM, Racoosin JA, Kortepeter C. Seizure activity and off-label use of tiagabine. N Eng J Med. 2006;354: 773-734.
7. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol. 1996;16: 101-103.
8. Thomsen MS, Groes L, Agersø H, et al. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol. 1998;38: 1051-1056.
9. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monitor. 2002;24: 91-103.
10. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43: 763-780.
11. Durham SL, Hoke JF, Chen TM. Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C] vigabatrin in healthy male volunteers. Drug Metab Disp. 1993;21: 480-484.
12. Rimmer E, Kongola G, Richens A. Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug. Br J Clin Pharmacol. 1988;25: 251-259.
13. Sanchez-Alcaraz A, Quintana B, Rodriguez I, et al. Plasma concentrations of vigabatrin in epileptic patients. J Clin Pharm Ther. 1996;21: 393-398.
14. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia. 1994;35: S10YS13.
15. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42: 1023-1042.
16. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol. 1990;39: 187-188.
17. Andreasen AH, Brøsen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007;48: 490-496.
18. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinyl estradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40: 783-787.
19. Klosterskov Jensen P, Saano V, Haring P, et al. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia. 1992;33: 1149-1152.
20. Muscatello MR, Pacetti M, Cacciola M, et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia. 2005;46: 771-774.
21. de Leon J, Santoro V, D'Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8: 311-334.
22. Theis JG, Sidhu J, Palmer J, et al. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology. 2005;30: 2269-2274.
23. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999;21: 175-181.
24. Weintraub D, Buchsbaum R, Resor SR Jr, et al. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62: 1432-1436.
25. O'Neill A, de Leon J. Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. Bipolar Disord. 2007;9: 310-313.
26. Nallani SC, Glauser TA, Hariparsad N, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44: 1521-1528.
27. Rosenfeld WE, Doose DR, Walker SA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38: 317-323.
28. Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44: 540-549.
29. Migliardi G, D'Arrigo C, Santoro V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone and quetiapine in patients with psychotic disorders. Clin Neuropharmacol. 2007;30: 107-113.
30. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1997;38: 324-333.
31. Vucievi K, Miljkovi B, Pokrajac M, et al. The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling. Eur J Pharm Sci. 2009;38: 512-518.
32. Doose DR, Brodie MJ, Wilson EA, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia. 2003;44: 917-922.
33. Wnuk W, Volanski A, Foletti G. Topiramate decreases lamotrigine concentrations. Ther Drug Monit. 1999;21: 449.
34. Reimers A, Skogvoll E, Sund JK, et al. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25: 342-348.
35. Richens A. Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Acta Neurol Scand Suppl. 1995;162: 43-46.
36. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol. 1989;27: 27SY33S.
37. Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol. 1993;36: 603-606.
38. Browne TR, Mattson RH, Penry JK, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol. 1989;27: 95SY100S.
39. Sheean G, Schramm T, Anderson DS, et al. VigabatrinVplasma enantiomer concentrations and clinical effects. Clin Exp Neurol. 1992;29: 107-116.
40. Seif-Eddeine H, Ng YT. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. Expert Rev Neurother. 2012;12: 385-393.
41. Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4: 138-144.
42. de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monitor. 2013;35: 30-47.
43. Greenblatt DJ, Divoll M, Puri SK, et al. Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. Clin Pharmacokinet. 1983;8: 83-94.
44. Walzer M, Bekersky I, Blum RA, et al. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32: 340-353.
45. Bun H, Coassolo P, Gouezo F, et al. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24: 287-293.
46. Bun H, Monjanel-Mouterde S, Noel F, et al. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol. 1990;67: 136-140.
47. Schmidt D, Rohde M, Wolf P, et al. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol. 1986;43: 824-826.
48. Muñoz JJ, De Salamanca RE, Diaz-Obregón C, et al. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. Br J Clin Pharmacol. 1990;29: 763-765.
49. Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit. 1992;14: 269-274.
50. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia. 1998;39: 1115-1118.